Destiny Pharma (LON:DEST) Sets New 12-Month Low at $7.60

Destiny Pharma plc (LON:DEST) hit a new 52-week low during trading on Tuesday . The stock traded as low as GBX 7.60 ($0.10) and last traded at GBX 8.65 ($0.11), with a volume of 401292 shares traded. The stock had previously closed at GBX 8.50 ($0.11).

Wall Street Analyst Weigh In

Separately, Shore Capital restated a “house stock” rating on shares of Destiny Pharma in a research report on Wednesday, June 12th.

Destiny Pharma Stock Performance

The company has a market capitalization of £8.24 million, a PE ratio of -144.17 and a beta of 0.31. The firm’s 50-day simple moving average is GBX 14.94 and its 200 day simple moving average is GBX 35.33.

About Destiny Pharma

Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of novel medicines to prevent serious infections in the United Kingdom. The company is involved in developing NTCD-M3 that is in Phase II clinical trial for the prevention of recurrent Clostridioides diffcile infections; XF-73 Nasal, which is in Phase II clinical trial for the prevention of post-surgical staphylococcal infection; and XF-73 Dermal that is in preclinical stage for the treatment of skin infections of antibiotic resistant bacteria, as well as superficial skin infections of antibiotic resistant bacteria.